Program
SAL056
A development code. Also written as “SAL056 56.5μg” and “SAL056 (56.5μg)”.
Its studies are mostly in Osteoporosis, led by Shenzhen Salubris Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 21 open or running | phase 3since Jun 11, 2025 | Jun 11, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 11, 2025First study: phase 3 study in Postmenopausal Women With OsteoporosisFirst studyNCT07028320 · 493 enrolled · China
- May 5, 2026Phase 2 study in Postmenopausal Women With OsteoporosisNCT07579936 · 200 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07579936Postmenopausal Women With Osteoporosis · China | 2 | Recruiting | Jul 30, 2026 | 200 |
| NCT07028320Postmenopausal Women With Osteoporosis · China | 3 | Completed | Dec 30, 2023 | 493 |
How it is read
Names in the registry
- “SAL056 56.5μg”, 1 entry
- “SAL056 (56.5μg)”, 1 entry
Codes read as this program: SAL056.
Conditions, from the studies’ own filings
- Osteoporosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.